HEARTSCIENCES INC. news, videos and press releases
For more news please use our advanced search feature.
HEARTSCIENCES INC. - More news...
HEARTSCIENCES INC. - More news...
- HeartSciences Provides Business Update and Reports Third Quarter Fiscal 2025 Financial Results
- HeartSciences Inc. Engages Integrous Communications to Enhance Investor Communications
- HeartSciences Provides Business Update and Reports Second Quarter Fiscal 2025 Financial Results
- HeartSciences’ AI-ECG Algorithms Assigned CMS Medicare and Medicaid Reimbursement
- HeartSciences to Participate in the 2024 Maxim Healthcare Virtual Summit
- HeartSciences Provides Business Update and Reports First Quarter Fiscal 2025 Financial Results
- HeartSciences Closes Non-Dilutive Financing to Increase its Cash Runaway Ahead of Upcoming FDA Submission
- HeartSciences Provides Business Update and Reports Fiscal 2024 Financial Results
- Innovation Value Institute Analysis Demonstrates HeartSciences’ MyoVista® wavECG™ Potential to Improve Cardiovascular Pathway Efficiency
- HeartSciences Selected to Demonstrate MyoVista® wavECG™ at the United Nations General Assembly Digital Health Symposium as a Technology to Radically Transform Healthcare
- HeartSciences Announces Allowance of U.S Patent for AI-ECG Assessment of Left Ventricular and Right Ventricular Heart Dysfunction
- HeartSciences Regains Compliance with Nasdaq Listing Requirements
- HeartSciences Announces Further Internationalization of its AI-ECG Patent Portfolio
- HeartSciences Announces Grant of Fundamental Patent by the European Patent Office Covering Assessment of Diastolic Function of the Heart Using AI-ECG
- HeartSciences to Present at the LD Micro Invitational XIV Conference
- HeartSciences Announces Podium Presentation at World Congress of Anesthesiologists on the Utility of MyoVista® Wavelet ECG For Detection of Left Ventricular Diastolic Dysfunction in Preoperative Patients
- HeartSciences Reports Third Quarter Fiscal 2024 Financial Results
- HeartSciences’ Announces Peer-Reviewed Publication Evaluating Use of MyoVista® Technology to Detect Asymptomatic Left Ventricular Dysfunction in Patients with Type 2 Diabetes
- HeartSciences Announces Canada Patent Grant Covering MyoVista® Wavelet Technology
- HeartSciences Adds Key Advisor to its Scientific Advisory Board
- HeartSciences Expands its Scientific Advisory Board
- HeartSciences Appoints New Scientific Advisory Board Member
- HeartSciences Announces Results and Adjournment of Annual Shareholder Meeting
- HeartSciences Reminds Stockholders to Vote at the Upcoming Annual Shareholder Meeting
- HeartSciences Reports Second Quarter Fiscal 2024 Financial Results
- HeartSciences Receives FDA Confirmation for 510(k) Clearance Pathway
- HeartSciences Announces Closing of License Agreements with the Icahn School of Medicine at Mount Sinai to Develop and Commercialize AI Cardiovascular Algorithms
- HeartSciences’ MyoVista® wavECGTM Selected for Heart Screening of Irish Garda National Police Officers
- HeartSciences Issues Investor Update Highlighting Recent Key Achievements and Positive Developments
- HeartSciences Receives Two New Patent Allowances, Expanding its International Patent Portfolio
